Immunitybio Inc ((IBRX)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ImmunityBio Inc. is conducting a study titled ‘ResQ117EX-ALC: Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy’. The study aims to evaluate the effectiveness of nogapendekin-alfa inbakicept (NAI) in reversing and maintaining ALC in patients with lymphopenia, a condition that significantly impacts survival rates in cancer patients undergoing standard treatments. This study addresses a critical unmet medical need as no current therapies exist for this purpose.
The intervention being tested is nogapendekin-alfa inbakicept, a drug administered via subcutaneous injection. It is intended to boost lymphocyte counts in patients receiving chemotherapy, immunotherapy, or radiation therapy, potentially improving their overall survival.
The study is designed as an expanded access program, meaning it provides the drug to patients who are not eligible for other clinical trials. There is no random allocation or masking involved, and the primary purpose is treatment.
The study was first submitted on April 25, 2025, with the last update submitted on July 7, 2025. These dates are crucial as they indicate the study’s progression and the availability of the latest information.
This update could positively influence ImmunityBio Inc.’s stock performance and investor sentiment, given the potential market for a treatment addressing lymphopenia. As no current competitors offer a similar solution, ImmunityBio could gain a significant advantage in the oncology market.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.